Obermatt
See Similar Stocks →

Tecan Group

SWX:TECN · CH0012100191
Life Sciences Tools & ServicesSmall

360

25
EV / EBIT26
Price / Owner Earnings86
Owner Earnings Yield1
Dividend Yield83
Price/Sales66
EV / Gross Profit78
Price/Book72
Return on Capital44
Cash Return on Capital41
Return on Equity34
EBIT Margin42
Gross Profitability54
Accruals85
Owner Earnings Margin38
Sales growth21
Profit Growth49
Long-Term EPS Growth54
Owner Earnings Growth1
Reinvestment66
Price momentum50
Debt load67
Refinancing73
Debt Payback1
Liquidity82
Analyst ratings23
Opinion Changes50
Price Target Upside31
Market mood63
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Tecan Group doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySwitzerland
IndustryLife Sciences Tools & Services
SizeSmall
TypePublic Company
ExchangeSWX
Employees1,395
Websitetecan.com
ISINCH0012100191
Last UpdateApr 2, 2026
Indices
Robotics & 3D PrintingSPI (Switzerland)
Themes
Machine LearningIndustrial AutomationHealth DiagnosticsImmunologyArtificial IntelligenceBiomedical EngineeringProcess AutomationGeneticsBiotechnology

Description

Tecan Group AG engages in the development, production, and distribution of enabling solutions for the discovery of pharmaceutical substances, as well as genomics, proteomics, and diagnostics. It provides platforms for the automation of laboratory pro…

Analysis

Middle-of-the-road

Tecan Group AG sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is adequate. The company scores 4/20 on our value-creation score: not creating value. Analyst sentiment is cautious.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
96
2023202420252026

All-time high

96

Jun 2026

All-time low

19

Jan 2026

Average rank

64

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
66
34
36
35
Price/Earnings
28
24
29
25
Price/Book
72
65
38
38
Dividend Yield
83
46
40
39
Value (overall)
81
70
42
41

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Tecan Group with its peers
Sartorius Stedim
PAR:DIM
15
CountryGermany
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Sartorius
GER:SRT
11
CountryGermany
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
AddLife
STO:ALIF B
83
CountrySweden
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Genfit
PAR:GNFT
32
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Lonza
VTX:LONN
54
CountrySwitzerland
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →
Eurofins Scientific
PAR:ERF
27
CountryLuxembourg
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →